Julien Asselineau
Papers
2
Total Citations
60
H-Index
2
About
Julien Asselineau is a clinical researcher whose work bridges surgical oncology and evidence-based medicine, with a focus on optimizing treatment strategies for urological and colorectal cancers. His major contributions center on comparative effectiveness research, particularly in evaluating minimally invasive versus traditional surgical approaches. In his landmark 2022 study from the UroCCR-47 series, he led a multicenter analysis comparing robotic-assisted partial nephrectomy (RPN) to open partial nephrectomy (OPN), demonstrating that RPN offers comparable oncologic outcomes with reduced morbidity—a finding that has garnered 46 citations and directly informs clinical decision-making for renal cancer patients. Asselineau also contributed to the GRECCAR 2 randomized phase 3 trial, which explored local excision versus total mesorectal excision for low rectal cancer patients with good response to neoadjuvant therapy, providing preliminary evidence that less radical surgery may be feasible in select cases. His work is characterized by rigorous methodology and a commitment to answering pressing clinical questions, making him a key voice in the shift toward personalized, function-preserving cancer care. With a growing citation impact, Asselineau continues to shape surgical standards through collaborative registry-based research.
Research Focus
Key Achievements
Top Papers
- 1
- 2